BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10125706)

  • 1. Multisource drugs: implications and concerns in the geriatric population.
    Gerbino PP; Joseph AS
    Hosp Pharm; 1993 Feb; 28(2):96-8, 101-2. PubMed ID: 10125706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projecting future drug expenditures--1994.
    Santell JP
    Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceuticals: Medicare Modernization Act--2005. End of Year Issue Brief.
    Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-21. PubMed ID: 16710928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
    Rai AK
    Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotechnology: will it break the health care bank?
    McGivney WT
    Physician Exec; 1992; 18(5):35-6. PubMed ID: 10121675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A vision of the pharmaceutical industry.
    Muñio S
    Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():5-9. PubMed ID: 9800720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 13. Similar concerns. Safety, costs among the issues to be weighed as FDA grapples with crafting an approval process for generic versions of biological medicines.
    Daly R
    Mod Healthc; 2011 Jul; 41(28):38-40. PubMed ID: 21853593
    [No Abstract]   [Full Text] [Related]  

  • 14. Multisource drug policies in Latin America: survey of 10 countries.
    Homedes N; Ugalde A
    Bull World Health Organ; 2005 Jan; 83(1):64-70. PubMed ID: 15682251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost of prescription drugs: rising concerns over equity, fairness and access to essential care.
    Work DR; Domino ME
    N C Med J; 2003; 64(6):270-4. PubMed ID: 14983614
    [No Abstract]   [Full Text] [Related]  

  • 16. WHO pulls Indian generics off AIDS drugs list.
    Nat Med; 2004 Sep; 10(9):885. PubMed ID: 15340402
    [No Abstract]   [Full Text] [Related]  

  • 17. Entry decisions in the generic pharmaceutical industry.
    Morton FM
    Rand J Econ; 1999; 30(3):421-40. PubMed ID: 10558596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM
    Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 20. Greater access to generic drugs. New FDA initiatives to improve drug reviews and reduce legal loopholes.
    Meadows M
    FDA Consum; 2003; 37(5):12-7. PubMed ID: 14666900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.